Teva Q1 2020
Business Results

2020 brought an unprecedented global health crisis, affecting all nations and industries, including the pharmaceutical industry, which plays many roles in countering the epidemic. As our industry responds to the challenge, we are reminded of the importance of reliable supplies of high quality generic medicines to meet critical demand. Teva has responded to this challenge by supporting efforts of governments and health services to curb the impact of the virus. We have done this while taking robust measures to safeguard the health and well-being of our employees, who have diligently worked to ensure that all our manufacturing and distribution facilities remain open to allow the safe supply of medicines and APIs to our customers, and to millions of patients around the world.

Our very strong results during the first quarter of 2020 were impacted by greater demand in our major markets for generic, OTC and respiratory products. Stronger revenues across these categories, along with growth in our operating and net profit, contributed to strong free cash flow and a further reduction in our net debt to $24.3 billion.

Looking ahead, in light of the challenges and uncertainties facing our industry and society at large, we will continue to take measures to safeguard our dedicated employees, securing continued operation of our supply chain and deliveries of our broad portfolio to the 200 million patients we serve.

Kåre Schultz
President & Chief Executive Officer

Our Q1 Financial Results and 2020 Guidance

	Revenue	EPS*	Free Cash Flow
Q1 Results:	**$4.4 billion**	**$0.76**	**$551 million**
Guidance:	$16.6 - $17.0 billion	$2.30 - $2.55	$1.8 - $2.2 billion

*Non-GAAP EPS







Q1 Business Highlights

AJOVY®
US FDA approved the AJOVY® (fremanezumab) autoinjector; first migraine anti-CGRP approved by NICE in UK

Launch of HERZUMA® (trastuzumab-pkrb) injection in the U.S. for the treatment of HER2-Overexpressing Breast Cancer

US FDA Approves ArmonAir® Digihaler™ (fluticasone propionate) Inhalation Powder, a digitally-integrated inhaler approved for use in asthma patients 12 years of age and older

BENDEKA®/TREANDA® orphan drug exclusivity extended to December 2022, with an additional positive ruling on 2031 BENDEKA patents

Teva's Response and Contributions to Mitigating the Impact of COVID-19

Business Continuity	**~200 million** patients continue to have access to our essential medicines	Minimal impact to our **R&D programs** and **product launches**	Positive evolution of **digital capabilities** for field sales force	**No job losses** related to COVID-19
Sourcing & Production	**Our facilities remain open** to meet demand for our essential medicines		**Adequate inventory** of raw materials and finished products across our global network	**Safe supply** and transport of our medicines and APIs remains largely uninterrupted
Our Employees	The **health and well-being** of our employees is our priority	Number of **people in our facilities limited** to only those who are essential and may not work remotely		Strict guidelines in place to protect and ensure safety of employees including **personal protective equipment, hygiene and social distancing**
Our Communities		**Supporting local government and healthcare** efforts to curb the pandemic	Millions of tablets of **investigational treatment** are being provided to governments and hospitals	Production of both API and finished doses for **potential treatments** are being secured and scaled

Cautionary Note Regarding Forward-Looking Statements

This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to:

- our ability to successfully compete in the marketplace, including: that we are substantially dependent on our generic products; consolidation of our customer base and commercial alliances among our customers; the increase in the number of competitors targeting generic opportunities and seeking U.S. market exclusivity for generic versions of significant products; competition for our specialty products, especially COPAXONE®, our leading medicine, which faces competition from existing and potential additional generic versions, competing glatiramer acetate products and orally-administered alternatives; the uncertainty of commercial success AUSTEDO®; competition from companies with greater resources and capabilities; delays in launches of new products and our ability to achieve expected results from investments in our product pipeline; ability to develop and commercialize biopharmaceutical products; efforts of pharmaceutical companies to limit the use of generics, including through legislation and regulations and the effectiveness of our patents and other measures to protect our intellectual property rights;
- our substantial indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments, may result in a further downgrade of our credit ratings; and our inability to raise debt or borrow funds in amounts or on terms that are favorable to us;
- the uncertainty of the magnitude, duration, geographic reach and impact of the COVID-19 outbreak on our business and on the economy in general; the current, and uncertain future, impact of the COVID-19 outbreak on our business, financial condition, operations, cash flows, and liquidity; the adequacy or effectiveness of steps we have taken or may take to respond to the COVID-19 outbreak;
- our business and operations in general, including manufacturing or quality control problems; interruptions in our supply chain, including due to potential effects of the COVID-19 outbreak on our operations and business in geographic locations impacted by the outbreak and on the business operations of our customers and suppliers; our ability to successfully execute and maintain the activities and efforts related to the COVID-19 measures over the long term and associated costs therewith; challenges associated with conducting business globally, including adverse effects of the COVID-19 pandemic; costs and delays resulting from the extensive governmental regulation to which we are subject, including effects on product approval due to the COVID-19 pandemic;
- our business and operations in general, including: implementation of our restructuring plan announced in December 2017; our ability to attract, hire and retain highly skilled personnel; our ability to develop and commercialize additional pharmaceutical products; compliance with anti-corruption, sanctions and trade control laws; manufacturing or quality control problems; interruptions in our supply chain including due to potential effects of the COVID-19 outbreak on our operations and business in geographic locations impacted by the outbreak and on the business operations of our customers and suppliers; our ability to successfully execute and maintain the activities and efforts related to the COVID-19 measures over the long term and associated costs therewith; challenges associated with conducting business globally, including adverse effects of the COVID-19 pandemic; costs and delays resulting from the extensive governmental regulation to which we are subject, including effects on product approval due to the COVID-19 pandemic; disruptions of information technology systems; breaches of our data security; variations in intellectual property laws; significant sales to a limited number of customers; our ability to successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions; our prospects and opportunities for growth if we sell assets and potential difficulties related to the operation of our new global enterprise resource planning (ERP) system;
- compliance, regulatory and litigation matters, including: increased legal and regulatory action in connection with public concern over the abuse of opioid medications in the U.S. and our ability to reach a final resolution of the remaining opioid-related litigation; costs and delays resulting from the extensive governmental regulation to which we are subject; the effects of reforms in healthcare regulation and reductions in pharmaceutical pricing, reimbursement and coverage; governmental investigations into S&M practices; potential liability for patent infringement; product liability claims; increased government scrutiny of our patent settlement agreements; failure to comply with complex Medicare and Medicaid reporting and payment obligations; and environmental risks;
- other financial and economic risks, including: our exposure to currency fluctuations and restrictions as well as credit risks; potential impairments of our intangible assets; potential significant increases in tax liabilities; and the effect on our overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in our business;

and other factors discussed in our 2019 Annual Report on Form 10-K, including in the sections captioned "Risk Factors" and "Forward-looking statements." Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.